Artwork

Innhold levert av Labiotech. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Labiotech eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

The future of combination vaccines

24:44
 
Del
 

Manage episode 436997453 series 3361449
Innhold levert av Labiotech. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Labiotech eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

The development of combination vaccines could represent a significant advancement in the fight against infectious diseases. With the potential to streamline the vaccination process and provide broader protection, these vaccines could greatly improve public health preparedness.

Moderna is harnessing the power of its mRNA platform to develop vaccines that target multiple respiratory viruses at once, including COVID-19, RSV, and influenza. The breakthrough technology enables the immune system to combat multiple pathogens simultaneously, revolutionizing immunization efforts and enhancing public health preparedness.

To look at combination vaccines, their usefulness and potential for the future, we had an in-depth conversation with Cesar Sanz Rodriguez, vice president, Europe & Switzerland, medical affairs, at Moderna.

00:45-02:53: What is combination vaccine technology?
02:53-05:33: What are the advantages of targeting multiple respiratory diseases simultaneously?
05:33-06:02: Making vaccinations more friendly
06:02-07:57: How does the immune system handle tackling many pathogens at the same time?
07:57-10:23: Is there an effect of efficacy with combination vaccines?
10:23-12:50: How do you manage different times between boosters?
12:50-13:57: Are many companies working on combination vaccines?
13:57-17:45: How easy is it to add vaccines, for example to tackle avian flu, into combination vaccines?
17:45-19:06: Is there a limit to the number of vaccines in a combination vaccine?
19:06-20:46: How easily can vaccines be updated to address variants?
20:46-22:30: What is the future of combination vaccines?
22:30-23:56: What is in Moderna’s pipeline related to vaccines?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Kapitler

1. The future of combination vaccines (00:00:00)

2. What is combination vaccine technology? (00:00:45)

3. What are the advantages of targeting multiple respiratory diseases simultaneously?
 (00:02:53)

4. Making vaccinations 'friendlier'
 (00:05:33)

5. How does the immune system handle tackling many pathogens at the same time?
 (00:06:02)

6. Is there an effect of efficacy with combination vaccines? (00:07:57)

7. How do you manage different times between boosters?
 (00:10:23)

8. Are many companies working on combination vaccines?
 (00:12:50)

9. How easy is it to add vaccines, for example to tackle avian flu, into combination vaccines?
 (00:13:57)

10. Is there a limit to the number of vaccines in a combination vaccine? 
 (00:17:45)

11. How easily can vaccines be updated to address variants?
 (00:19:06)

12. What is the future of combination vaccines?
 (00:20:46)

13. What is in Moderna’s pipeline related to vaccines? (00:22:30)

129 episoder

Artwork
iconDel
 
Manage episode 436997453 series 3361449
Innhold levert av Labiotech. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Labiotech eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

The development of combination vaccines could represent a significant advancement in the fight against infectious diseases. With the potential to streamline the vaccination process and provide broader protection, these vaccines could greatly improve public health preparedness.

Moderna is harnessing the power of its mRNA platform to develop vaccines that target multiple respiratory viruses at once, including COVID-19, RSV, and influenza. The breakthrough technology enables the immune system to combat multiple pathogens simultaneously, revolutionizing immunization efforts and enhancing public health preparedness.

To look at combination vaccines, their usefulness and potential for the future, we had an in-depth conversation with Cesar Sanz Rodriguez, vice president, Europe & Switzerland, medical affairs, at Moderna.

00:45-02:53: What is combination vaccine technology?
02:53-05:33: What are the advantages of targeting multiple respiratory diseases simultaneously?
05:33-06:02: Making vaccinations more friendly
06:02-07:57: How does the immune system handle tackling many pathogens at the same time?
07:57-10:23: Is there an effect of efficacy with combination vaccines?
10:23-12:50: How do you manage different times between boosters?
12:50-13:57: Are many companies working on combination vaccines?
13:57-17:45: How easy is it to add vaccines, for example to tackle avian flu, into combination vaccines?
17:45-19:06: Is there a limit to the number of vaccines in a combination vaccine?
19:06-20:46: How easily can vaccines be updated to address variants?
20:46-22:30: What is the future of combination vaccines?
22:30-23:56: What is in Moderna’s pipeline related to vaccines?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Kapitler

1. The future of combination vaccines (00:00:00)

2. What is combination vaccine technology? (00:00:45)

3. What are the advantages of targeting multiple respiratory diseases simultaneously?
 (00:02:53)

4. Making vaccinations 'friendlier'
 (00:05:33)

5. How does the immune system handle tackling many pathogens at the same time?
 (00:06:02)

6. Is there an effect of efficacy with combination vaccines? (00:07:57)

7. How do you manage different times between boosters?
 (00:10:23)

8. Are many companies working on combination vaccines?
 (00:12:50)

9. How easy is it to add vaccines, for example to tackle avian flu, into combination vaccines?
 (00:13:57)

10. Is there a limit to the number of vaccines in a combination vaccine? 
 (00:17:45)

11. How easily can vaccines be updated to address variants?
 (00:19:06)

12. What is the future of combination vaccines?
 (00:20:46)

13. What is in Moderna’s pipeline related to vaccines? (00:22:30)

129 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2025 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett
Lytt til dette showet mens du utforsker
Spill